发布求助

文献互助智能选刊最新文献

特刊：摘要增刊 HIV 格拉斯哥 2024 年 11 月 10-13 日，英国格拉斯哥/虚拟。

IF 4.6 1区医学 Q2 IMMUNOLOGY

Journal of the International AIDS Society Pub Date : 2024-11-08 DOI:10.1002/jia2.26370

{"title":"特刊：摘要增刊 HIV 格拉斯哥 2024 年 11 月 10-13 日，英国格拉斯哥/虚拟。","authors":"","doi":"10.1002/jia2.26370","DOIUrl":null,"url":null,"abstract":"Commonly-used Abbreviations 1Oral PresentationsExperience in the Implementation of Long-Acting Treatment 3Antiretroviral Treatment Strategies 5Infection Prevention 6Integrase Strand Transfer Inhibitor (INSTI) Resistance 7Co-morbidities and Co-infections 9PrEP-ing for the Future 17Poster PresentationsARV-based prevention—Vertical transmission 20ARV-based prevention—PEP 28ARV-based prevention—PrEP 29Treatment strategies—Novel therapeutic targets (phase I and II) 45Treatment strategies—RCTs: Oral and injectable therapy in first line and suppressed switch populations 47Treatment strategies—Real-world and implementation science studies oral and injectable therapy 66Treatment strategies—Treatment experienced adults (second line and multi-drug resistance studies) 122Treatment strategies—Models of care for ageing/frail populations including virological failure and switching 147Treatment strategies—Rapid ART initiation 149Treatment strategies—Adherence 158Clinical management considerations—Women 164Clinical management considerations—Late presenters 170Clinical management considerations—People who inject drugs (PWID) 180Clinical management considerations—Transgender people 181Clinical management considerations—Adolescents 182Clinical management considerations—Paediatrics 183Clinical management considerations—Drug-drug interactions 187Cure/post-treatment control 194Opportunistic infections and AIDS-defining cancers 200Clinical pharmacology 206Community-based treatment and prevention initiatives, including primary care screening 209Public health strategies including of policy options 219Cost and cost-effectiveness 233Models of care: evaluation of ARV delivery and coverage 237Co-morbidities and complications of disease and/or treatment—Ageing and frailty 245Co-morbidities and complications of disease and/or treatment—Cardiovascular/metabolic including weight gain 249Co-morbidities and complications of disease and/or treatment—Malignancies: non-AIDS defining 273Co-morbidities and complications of disease and/or treatment—Neurological 280Co-morbidities and complications of disease and/or treatment—Renal 282Co-morbidities and complications of disease and/or treatment—Mental health disorders 287Co-morbidities and complications of disease and/or treatment—Other 291People living with HIV and COVID-19: Outcomes 304People living with HIV and mpox virus 307People living with HIV and sexually transmitted diseases 311People living with HIV and tuberculosis 320People living with HIV and viral hepatitis 323People living with HIV and other diseases 329Author Index 335","PeriodicalId":201,"journal":{"name":"Journal of the International AIDS Society","volume":"27 S6","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jia2.26370","citationCount":"0","resultStr":"{\"title\":\"Abstract Supplement HIV Glasgow 10–13 November 2024, Glasgow, UK/Virtual\",\"authors\":\"\",\"doi\":\"10.1002/jia2.26370\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Commonly-used Abbreviations 1Oral PresentationsExperience in the Implementation of Long-Acting Treatment 3Antiretroviral Treatment Strategies 5Infection Prevention 6Integrase Strand Transfer Inhibitor (INSTI) Resistance 7Co-morbidities and Co-infections 9PrEP-ing for the Future 17Poster PresentationsARV-based prevention—Vertical transmission 20ARV-based prevention—PEP 28ARV-based prevention—PrEP 29Treatment strategies—Novel therapeutic targets (phase I and II) 45Treatment strategies—RCTs: Oral and injectable therapy in first line and suppressed switch populations 47Treatment strategies—Real-world and implementation science studies oral and injectable therapy 66Treatment strategies—Treatment experienced adults (second line and multi-drug resistance studies) 122Treatment strategies—Models of care for ageing/frail populations including virological failure and switching 147Treatment strategies—Rapid ART initiation 149Treatment strategies—Adherence 158Clinical management considerations—Women 164Clinical management considerations—Late presenters 170Clinical management considerations—People who inject drugs (PWID) 180Clinical management considerations—Transgender people 181Clinical management considerations—Adolescents 182Clinical management considerations—Paediatrics 183Clinical management considerations—Drug-drug interactions 187Cure/post-treatment control 194Opportunistic infections and AIDS-defining cancers 200Clinical pharmacology 206Community-based treatment and prevention initiatives, including primary care screening 209Public health strategies including of policy options 219Cost and cost-effectiveness 233Models of care: evaluation of ARV delivery and coverage 237Co-morbidities and complications of disease and/or treatment—Ageing and frailty 245Co-morbidities and complications of disease and/or treatment—Cardiovascular/metabolic including weight gain 249Co-morbidities and complications of disease and/or treatment—Malignancies: non-AIDS defining 273Co-morbidities and complications of disease and/or treatment—Neurological 280Co-morbidities and complications of disease and/or treatment—Renal 282Co-morbidities and complications of disease and/or treatment—Mental health disorders 287Co-morbidities and complications of disease and/or treatment—Other 291People living with HIV and COVID-19: Outcomes 304People living with HIV and mpox virus 307People living with HIV and sexually transmitted diseases 311People living with HIV and tuberculosis 320People living with HIV and viral hepatitis 323People living with HIV and other diseases 329Author Index 335\",\"PeriodicalId\":201,\"journal\":{\"name\":\"Journal of the International AIDS Society\",\"volume\":\"27 S6\",\"pages\":\"\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2024-11-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jia2.26370\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the International AIDS Society\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jia2.26370\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the International AIDS Society","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jia2.26370","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

常用缩略语 1口头报告实施长效治疗的经验 3抗逆转录病毒治疗策略 5感染预防 6整合酶链转移抑制剂（INSTI）耐药性 7合并疾病和合并感染 9PrEP-面向未来 17海报报告基于ARV的预防-垂直传播 20基于ARV的预防-PEP 28基于ARV的预防-PrEP 29治疗策略-新的治疗目标（I期和II期） 45治疗策略-RCTs：治疗策略--口服和注射疗法在一线和抑制性转换人群中的应用 47治疗策略--口服和注射疗法的实际应用和实施科学研究 66治疗策略--有治疗经验的成人（二线和多药耐药性研究治疗策略-治疗经验丰富的成人（二线和多药耐药性研究） 122治疗策略-老龄/体弱人群的护理模式，包括病毒学失败和转换 147治疗策略-快速启动抗逆转录病毒疗法 149治疗策略-依从性 158临床管理注意事项-女性 164临床管理注意事项-晚期患者 170临床管理注意事项-注射吸毒者（PWID） 180临床管理注意事项-变性人 181临床管理注意事项-青少年 182临床管理注意事项-儿科 183临床管理注意事项-药物-药物相互作用药物相互作用 187治疗/治疗后控制 194机会性感染和艾滋病定义的癌症 200临床药理学 206基于社区的治疗和预防措施、包括初级保健筛查 209 公共卫生战略，包括政策选择 219 成本和成本效益 233 护理模式：疾病和/或治疗并发症-老龄化和虚弱 245疾病和/或治疗并发症-心血管/代谢，包括体重增加 249疾病和/或治疗并发症-恶性肿瘤：疾病和/或治疗的并发症-神经系统 280疾病和/或治疗的并发症-肾脏 282疾病和/或治疗的并发症-精神疾病 287疾病和/或治疗的并发症-其他 291艾滋病毒感染者和COVID-19：艾滋病病毒感染者与 COVID-19：结果 304艾滋病病毒感染者与 mpox 病毒 307艾滋病病毒感染者与性传播疾病 311艾滋病病毒感染者与结核病 320艾滋病病毒感染者与病毒性肝炎 323艾滋病病毒感染者与其他疾病 329作者索引 335

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Abstract Supplement HIV Glasgow 10–13 November 2024, Glasgow, UK/Virtual

查看原文本刊更多论文

Abstract Supplement HIV Glasgow 10–13 November 2024, Glasgow, UK/Virtual

Commonly-used Abbreviations 1

Oral Presentations

Experience in the Implementation of Long-Acting Treatment 3

Antiretroviral Treatment Strategies 5

Infection Prevention 6

Integrase Strand Transfer Inhibitor (INSTI) Resistance 7

Co-morbidities and Co-infections 9

PrEP-ing for the Future 17

Poster Presentations

ARV-based prevention—Vertical transmission 20

ARV-based prevention—PEP 28

ARV-based prevention—PrEP 29

Treatment strategies—Novel therapeutic targets (phase I and II) 45

Treatment strategies—RCTs: Oral and injectable therapy in first line and suppressed switch populations 47

Treatment strategies—Real-world and implementation science studies oral and injectable therapy 66

Treatment strategies—Treatment experienced adults (second line and multi-drug resistance studies) 122

Treatment strategies—Models of care for ageing/frail populations including virological failure and switching 147

Treatment strategies—Rapid ART initiation 149

Treatment strategies—Adherence 158

Clinical management considerations—Women 164

Clinical management considerations—Late presenters 170

Clinical management considerations—People who inject drugs (PWID) 180

Clinical management considerations—Transgender people 181

Clinical management considerations—Adolescents 182

Clinical management considerations—Paediatrics 183

Clinical management considerations—Drug-drug interactions 187

Cure/post-treatment control 194

Opportunistic infections and AIDS-defining cancers 200

Clinical pharmacology 206

Community-based treatment and prevention initiatives, including primary care screening 209

Public health strategies including of policy options 219

Cost and cost-effectiveness 233

Models of care: evaluation of ARV delivery and coverage 237

Co-morbidities and complications of disease and/or treatment—Ageing and frailty 245

Co-morbidities and complications of disease and/or treatment—Cardiovascular/metabolic including weight gain 249

Co-morbidities and complications of disease and/or treatment—Malignancies: non-AIDS defining 273

Co-morbidities and complications of disease and/or treatment—Neurological 280

Co-morbidities and complications of disease and/or treatment—Renal 282

Co-morbidities and complications of disease and/or treatment—Mental health disorders 287

Co-morbidities and complications of disease and/or treatment—Other 291

People living with HIV and COVID-19: Outcomes 304

People living with HIV and mpox virus 307

People living with HIV and sexually transmitted diseases 311

People living with HIV and tuberculosis 320

People living with HIV and viral hepatitis 323

People living with HIV and other diseases 329

Author Index 335

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of the International AIDS Society IMMUNOLOGY-INFECTIOUS DISEASES

CiteScore

8.60

自引率

10.00%

发文量

186

审稿时长

>12 weeks

期刊介绍： The Journal of the International AIDS Society (JIAS) is a peer-reviewed and Open Access journal for the generation and dissemination of evidence from a wide range of disciplines: basic and biomedical sciences; behavioural sciences; epidemiology; clinical sciences; health economics and health policy; operations research and implementation sciences; and social sciences and humanities. Submission of HIV research carried out in low- and middle-income countries is strongly encouraged.